Stock ERNA ETERNA THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Eterna Therapeutics Inc.

Equities

ERNA

US1140822099

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-06-25 EDT 		5-day change 1st Jan Change
1.82 USD -1.64% Intraday chart for Eterna Therapeutics Inc. -7.63% +1.37%
05-14 Eterna Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-08 Eterna Therapeutics Inc. Appoints Mahendra Rao to Its Scientific Advisory Board CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
AQ
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
AQ
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
AQ
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
AQ
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
AQ
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
AQ
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
AQ
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
AQ
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
AQ
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
AQ
Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing
AQ
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors
AQ
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics
AQ
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights
AQ
Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
AQ
Eterna Therapeutics : Material Agreement - Form 8-K
PU
Eterna Therapeutics : Material Agreement - Form 8-K
PU
Eterna Therapeutics : Failure to Satisfy Listing Rule - Form 8-K
PU
BROOKLYN IMMUNOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
BROOKLYN IMMUNOTHERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ERNA Stock
  4. News Eterna Therapeutics Inc.
  5. Press Releases